22157.jpg
Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides
March 13, 2024 11:26 ET | Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
intrommune_icon_500x500.png
Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
March 12, 2024 11:01 ET | Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
Global Kaposi Sarcoma Market
Global Kaposi Sarcoma Market Analysis 2024-2034: HAART Emerges as a Game-Changer in HIV Treatment, Paving the Way for Control and Prevention of AIDS-Associated Kaposi Sarcoma
March 11, 2024 13:46 ET | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Kaposi Sarcoma Market by Type, by Treatment, by End-Users, and By Region" report has been added to ResearchAndMarkets.com's offering. The...
22157.jpg
Interleukin-2 (IL-2) Inhibitor Drug Pipeline Research Report 2024
March 05, 2024 03:30 ET | Research and Markets
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET | BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
purple-logo2020.png
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024 07:00 ET | Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Turnstone Logo.jpg
Turnstone Biologics to Participate in Upcoming Investor Conferences
February 21, 2024 06:00 ET | Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
Chinese Oncology Drugs Market
China Oncology Drugs Market Report, 2023 and 2024-2028 - Cancer Prevention Takes Center Stage in China's National Health Agenda
February 19, 2024 07:48 ET | Research and Markets
Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "China Oncology Drugs Market, Size, Forecast 2024-2028, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Global Allergy Immunotherapy Market
Allergy Immunotherapy Soars: Anticipating a $2.69 Billion Market by 2028 with an Impressive CAGR of 8.12%
February 05, 2024 04:41 ET | Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Allergy Immunotherapy Market (2023-2028) by Type, Application and Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19,...